SR 31747

In vivo, SR-31747 dramatically blocks lipopolysaccharide-induced production of IL-1, IL-6 and TNF-α in a dose-dependent manner (ED₅₀, 2 mg/kg). SR-31747 probably abrogated monokine production through an indirect mechanism that involves endogenous corticosteroids. This conclusion was supported by in vivo experiments that shows that: 1) ablation of corticosteroids by use of Mifepristone or adrenalectomy suppress the effect of SR-31747; 2) administration of SR-31747 induces an enhancement of the corticosterone level. SR-31747 improves the survival of animals with endotoxinic shock as a result of monokine inhibition^[1].